Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021; 23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Pringl Miller, MD, Preeti R. John, MD, MPH, and Sabha Ganai, MD, PhD, MPH
A surgeon’s duty is to identify goals of care, including those about quality of life, from a patient’s perspective and to consider how to achieve them.
AMA J Ethics. 2021; 23(10):E778-782. doi:
10.1001/amajethics.2021.778.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
COVID-19 underscores historical precedent for fear-driven responses that disregard autonomy among persons with low income who are also persons of color.
AMA J Ethics. 2021; 23(11):E840-846. doi:
10.1001/amajethics.2021.840.
Patients can now easily view their health records, so clinicians must consider a reader’s interpretation of how they convey sensitive personal health information. What might this mean for ethics consultants?
AMA J Ethics. 2020; 22(9):E784-791. doi:
10.1001/amajethics.2020.784.
Most women requesting pregnancy termination have already decided to undergo an abortion, but some jurisdictions have implemented strategies to induce doubt and regret.
AMA J Ethics. 2020; 22(9):E792-795. doi:
10.1001/amajethics.2020.792.